MX2011008614A - Formulacion de doramectina en dosis elevada. - Google Patents

Formulacion de doramectina en dosis elevada.

Info

Publication number
MX2011008614A
MX2011008614A MX2011008614A MX2011008614A MX2011008614A MX 2011008614 A MX2011008614 A MX 2011008614A MX 2011008614 A MX2011008614 A MX 2011008614A MX 2011008614 A MX2011008614 A MX 2011008614A MX 2011008614 A MX2011008614 A MX 2011008614A
Authority
MX
Mexico
Prior art keywords
doramectin
high dosage
formulation
dose
doramectin formulation
Prior art date
Application number
MX2011008614A
Other languages
English (en)
Inventor
Alvimar Jose Costa
Stephen Lee Secreast
Rodrigo Valarelli
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2011008614A publication Critical patent/MX2011008614A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen composiciones veterinarias que proporcionan una dosis elevada de doramectina o una composición politerápica veterinaria en dosis elevada que comprende doramectina y un antiparasitario o más; las composiciones dan a conocer una eficacia antiparasitaria y un tiempo de retención significativamente reducido.
MX2011008614A 2009-02-16 2010-02-02 Formulacion de doramectina en dosis elevada. MX2011008614A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15291109P 2009-02-16 2009-02-16
US21983709P 2009-06-24 2009-06-24
PCT/IB2010/050443 WO2010116267A1 (en) 2009-02-16 2010-02-02 High dosage doramectin formulation

Publications (1)

Publication Number Publication Date
MX2011008614A true MX2011008614A (es) 2011-09-09

Family

ID=42060687

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008614A MX2011008614A (es) 2009-02-16 2010-02-02 Formulacion de doramectina en dosis elevada.

Country Status (20)

Country Link
US (1) US8551962B2 (es)
EP (1) EP2396006B1 (es)
JP (1) JP2012517994A (es)
KR (1) KR101326428B1 (es)
CN (1) CN102316876B (es)
AR (1) AR075428A1 (es)
AU (1) AU2010233409B2 (es)
BR (1) BRPI1008822B1 (es)
CA (1) CA2750626C (es)
CL (1) CL2011001775A1 (es)
CO (1) CO6410307A2 (es)
DK (1) DK2396006T3 (es)
ES (1) ES2399228T3 (es)
HK (1) HK1161087A1 (es)
MX (1) MX2011008614A (es)
NZ (1) NZ594389A (es)
PL (1) PL2396006T3 (es)
PT (1) PT2396006E (es)
WO (1) WO2010116267A1 (es)
ZA (1) ZA201105310B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9616044B2 (en) 2012-03-13 2017-04-11 Bayer New Zealand Ltd Long acting compositions
ES2436249B1 (es) * 2012-06-25 2014-06-23 Javier Alberto ALONSO-VAQUERO VELASCO Composición antiparasitaria para el control y tratamiento de parásitos de diferentes especies animales, caracterizada por combinar Moxidectina con las vitaminas: A, D3, y E
WO2014098623A1 (en) * 2012-12-20 2014-06-26 Alleva Animal Health Limited Injectable eprinomectin formulation and anthelmintic use thereof
CN103977017B (zh) * 2014-06-03 2016-09-07 重庆布尔动物药业有限公司 一种兽用抗寄生虫注射液及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8800986A1 (es) 1985-07-27 1987-12-01 Pfizer Un procedimiento para la produccion de un nuevo derivado de avermectina
US6001822A (en) 1989-04-11 1999-12-14 Pfizer Inc. Antiparasitic formulations
ES2052173T3 (es) 1989-04-11 1994-07-01 Pfizer Composiciones inyectables que contienen 25-cyclohexil-avermectina b1.
WO1997011709A1 (en) * 1995-09-25 1997-04-03 Ashmont Holdings Limited Anthelmintic macrocyclic lactone compositions
DE19613972A1 (de) 1996-04-09 1997-10-16 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen auf Basis von Rizinusöl
AU728221B2 (en) 1996-06-05 2001-01-04 Ashmont Holdings Limited Injectable compositions
DE19638045A1 (de) * 1996-09-18 1998-03-19 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen
US6174540B1 (en) 1998-09-14 2001-01-16 Merck & Co., Inc. Long acting injectable formulations containing hydrogenated caster oil
KR20000025762A (ko) * 1998-10-14 2000-05-06 유충식 이버멕틴류의 가용화 조성물
GB9825402D0 (en) * 1998-11-19 1999-01-13 Pfizer Ltd Antiparasitic formulations
GB9827727D0 (en) 1998-12-16 1999-02-10 Pfizer Ltd Antiparasitic formulations
CN1304727A (zh) * 2000-10-20 2001-07-25 王玉万 一种以苯甲酸苄酯或氮酮为助溶剂的含阿维菌素或伊维菌素的注射液

Also Published As

Publication number Publication date
EP2396006A1 (en) 2011-12-21
NZ594389A (en) 2012-09-28
ES2399228T3 (es) 2013-03-26
US20110294751A1 (en) 2011-12-01
PL2396006T3 (pl) 2013-06-28
KR20110116231A (ko) 2011-10-25
CA2750626A1 (en) 2010-10-14
US8551962B2 (en) 2013-10-08
HK1161087A1 (en) 2012-08-24
AR075428A1 (es) 2011-03-30
BRPI1008822B1 (pt) 2019-04-09
CN102316876B (zh) 2013-07-17
CO6410307A2 (es) 2012-03-30
CL2011001775A1 (es) 2011-10-28
DK2396006T3 (da) 2013-02-11
WO2010116267A1 (en) 2010-10-14
PT2396006E (pt) 2013-02-13
CA2750626C (en) 2013-10-01
AU2010233409B2 (en) 2012-05-17
AU2010233409A1 (en) 2011-08-11
EP2396006B1 (en) 2012-12-19
CN102316876A (zh) 2012-01-11
JP2012517994A (ja) 2012-08-09
KR101326428B1 (ko) 2013-11-20
ZA201105310B (en) 2012-09-26
BRPI1008822A2 (pt) 2016-03-08

Similar Documents

Publication Publication Date Title
PH12014502880A1 (en) Lyophilized therapeutic peptibody formulations
MX2010014041A (es) Una forma cristalina de posaconazol.
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
NZ746271A (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
MY149529A (en) Novel agricultural composition
MX2009013810A (es) Uso de homo y copolimeros para la estabilizacion de formulaciones de principios activos.
RS54815B1 (sr) Supstanca koja sadrži antibiotik i disperzant
MX336741B (es) Composiciones farmaceuticas de moduladores de c-met.
MX2012001800A (es) Composicion para el cuidado oral que comprende agente sesquiterpenoide y antimicrobiano.
PL1981915T3 (pl) Kompozycje składników aktywnych
WO2010111640A3 (en) Anti-influenza formulations and methods
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
MY160565A (en) Chalcones as enhancer of antimicrobial agents
MX2009008542A (es) Agentes de suministro de acido fenilalquilcarboxilico.
MX2012007365A (es) Composiciones farmaceuticas de liberacion lenta de iloperidona.
WO2012096718A3 (en) Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers, and liver health maintenance
EP2015740A4 (en) NEW LOW-DOSED PHARMACEUTICAL COMPOSITIONS WITH NIMESULID, PREPARATION AND USE
MX2012001498A (es) Composicion antimicrobiana sinergica.
TW200738627A (en) Trialkylsilyl-indoles
NZ596628A (en) Ketolide compounds having antimicrobial activity
GB0606212D0 (en) Pharmaceutical compositions
MX2013006493A (es) Composiciones para el cuidado bucal que comprende una quinona y un agente antimicrobiano adicional.
MX2011008614A (es) Formulacion de doramectina en dosis elevada.
MX2009012370A (es) Formulacion de antraciclina de baja viscosidad.
GEP201706717B (en) Fibrinolytic compositions comprising bromelain and nattokinase for prevention and treatment of phlebothrombtic states

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ZOETIS LLC

HC Change of company name or juridical status

Owner name: ZOETIS LLC

FG Grant or registration